Europeiska unionen - bulgariska - EMA (European Medicines Agency)

novartis europharm ltd. - алискирена, амлодипина, гидрохлортиазида - Хипертония - Сърдечносъдова система - rasitrio е показан за лечение на есенциална хипертония като субституиращата терапия при възрастни пациенти, чието кръвно налягане е адекватно контролирано на комбинацията от aliskiren, амлодипин и хидрохлоротиазид дава едновременно в същата доза ниво в комбинация.

Europeiska unionen - bulgariska - EMA (European Medicines Agency)

novartis europharm ltd - алискирена, амлодипина - Хипертония - Агенти, действащи върху системата ренин-ангиотензин - rasilamlo е показан за лечение на есенциална хипертония при възрастни пациенти, чието кръвно налягане не се контролира адекватно с употребата на алискирен или амлодипин.

Bulgarien - bulgariska - Изпълнителна агенция по лекарствата

20 mg/5 mg film - coated tablets

Bulgarien - bulgariska - Изпълнителна агенция по лекарствата

40 mg/5 mg film - coated tablets

Bulgarien - bulgariska - Изпълнителна агенция по лекарствата

40 mg/10 mg film - coated tablets

Bulgarien - bulgariska - Изпълнителна агенция по лекарствата

40 mg/5 mg film - coated tablets

Europeiska unionen - bulgariska - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - Телмисартан - Хипертония - Сърдечносъдова система - Лечение эссенциальной хипертония при възрастни:добавяне на therapyonduarp, се посочва в възрастни, чието кръвно налягане не се контролира адекватно амлодипином. Подмяна на therapyadult на пациентите за получаване на телмисартан и Амлодипин от индивидуалните таблетки могат да се появят хапчета onduarp съдържащи еднакви дози компонент .

Bulgarien - bulgariska - Изпълнителна агенция по лекарствата

krka, d.d. novo mesto - Амлодипин, Аторвастатин - 5 mg/10 mg film - coated tablets

Europeiska unionen - bulgariska - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - Антинеопластични средства - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Europeiska unionen - bulgariska - EMA (European Medicines Agency)

samsung bioepis nl b.v. - бевацизумаб - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Антинеопластични средства - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. За повече информация, както за човешкия рецептор на епидермален фактор за растеж 2 (her2 и) статут, моля, вижте раздел 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. За допълнителна информация относно статуса на her2, моля, вижте раздел 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).